Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

doi:10.1182/bloodadvances.2020003698

	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
	Yang, Haiyan 7; Xiang, Bing 8; Song, Yuqin 9; Zhang, Huilai 10; Zhao, Weili 11; Zou, Dehui 12; Lv, Fangfang 1; Guo, Wei 13; Liu, Aichun 6; Li, Caixia 5
刊名	BLOOD ADVANCES
	2022-03-22
卷号	6
ISSN号	2473-9529
DOI	10.1182/bloodadvances.2020003698
通讯作者	Li, Yufu(liyufu439@126.com)
英文摘要	The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4 patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade $ 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.
资助项目	BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
WOS关键词	NON-HODGKIN-LYMPHOMA ; IMMUNOHISTOCHEMISTRY ; IBRUTINIB ; SURVIVAL
WOS研究方向	Hematology
语种	英语
出版者	ELSEVIER
WOS记录号	WOS:000792486200001
资助机构	BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130923]
专题	中国科学院合肥物质科学研究院
通讯作者	Li, Yufu
作者单位	1.Fudan Univ, Shanghai Canc Hosp, Dept Oncol, Shanghai, Peoples R China 2.Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China 3.BeiGene USA Inc, San Mateo, CA USA 4.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China 5.Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China 6.Harbin Med Univ, Canc Hosp, Dept Hematol & Lymphoma, Harbin, Peoples R China 7.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc,Canc Hosp, Hangzhou, Peoples R China 8.West China Hosp, Sichuan Hosp, Dept Hematol, Chengdu, Peoples R China 9.Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China 10.Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China
推荐引用方式 GB/T 7714	Yang, Haiyan,Xiang, Bing,Song, Yuqin,et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma[J]. BLOOD ADVANCES,2022,6.
APA	Yang, Haiyan.,Xiang, Bing.,Song, Yuqin.,Zhang, Huilai.,Zhao, Weili.,...&Li, Yufu.(2022).Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.BLOOD ADVANCES,6.
MLA	Yang, Haiyan,et al."Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma".BLOOD ADVANCES 6(2022).